Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 5031529, 7 pages
http://dx.doi.org/10.1155/2016/5031529
Research Article

Allogeneic Antigen Composition for Preparing Universal Cancer Vaccines

1Department of Proteomic Research and Mass Spectrometry, Institute of Biomedical Chemistry, Moscow, Russia
2BioBohemia Ltd., Moscow, Russia

Received 15 February 2016; Revised 8 June 2016; Accepted 28 August 2016

Academic Editor: Mercedes López

Copyright © 2016 Petr G. Lokhov and Elena E. Balashova. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Okaji, N. H. Tsuno, S. Saito et al., “Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy,” European Journal of Surgical Oncology, vol. 32, no. 4, pp. 363–370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. N. Hart, K. L. Sadewasser, P. A. Cancilla, and L. E. DeBault, “Experimental autoimmune type of vasculitis resulting from activation of mouse lymphocytes to cultured endothelium,” Laboratory Investigation, vol. 48, no. 4, pp. 419–427, 1983. View at Google Scholar · View at Scopus
  3. M. Matsuda, “Experimental glomerular tissue injury induced by immunization with cultured endothelial cell plasma membrane,” Acta Pathologica Japonica, vol. 38, no. 7, pp. 823–829, 1988. View at Google Scholar · View at Scopus
  4. P. G. Lokhov and E. E. Balashova, “Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro,” Human Vaccines & Immunotherapeutics, vol. 9, no. 1, pp. 198–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. P. G. Lokhov and E. E. Balashova, “Universal cancer vaccine: an update on the design of cancer vaccines generated from endothelial cells,” Human Vaccines and Immunotherapeutics, vol. 9, no. 7, pp. 1549–1552, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. P. G. Lokhov and E. E. Balashova, “Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC),” Human Vaccines and Immunotherapeutics, vol. 11, no. 3, pp. 689–698, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Rittié and G. J. Fisher, “Isolation and culture of skin fibroblasts,” Methods in Molecular Medicine, vol. 117, pp. 83–98, 2005. View at Google Scholar · View at Scopus
  8. P. Lokhov, E. Balashova, and M. Dashtiev, “Cell proteomic footprint,” Rapid Communications in Mass Spectrometry, vol. 23, no. 5, pp. 680–682, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Folkman, C. C. Haudenschild, and B. R. Zetter, “Long-term culture of capillary endothelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 10, pp. 5217–5221, 1979. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Romani, S. Gruner, D. Brang et al., “Proliferating dendritic cell progenitors in human blood,” The Journal of Experimental Medicine, vol. 180, no. 1, pp. 83–93, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. C. O. Yun, K. F. Nolan, E. J. Beecham, R. A. Reisfeld, and R. P. Junghans, “Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin t-cell receptors,” Neoplasia, vol. 2, no. 5, pp. 449–459, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. C. L.-L. Chiang, F. Benencia, and G. Coukos, “Whole tumor antigen vaccines,” Seminars in Immunology, vol. 22, no. 3, pp. 132–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. T. D. De Gruijl, A. J. M. Van Den Eertwegh, H. M. Pinedo, and R. J. Scheper, “Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines,” Cancer Immunology, Immunotherapy, vol. 57, no. 10, pp. 1569–1577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. Cheever, J. P. Allison, A. S. Ferris et al., “The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research,” Clinical Cancer Research, vol. 15, no. 17, pp. 5323–5337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Lang, A.-C. Andrei, and D. G. McNeel, “Prioritization of cancer antigens: keeping the target in sight,” Expert Review of Vaccines, vol. 8, no. 12, pp. 1657–1661, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. E. E. Balashova and P. G. Lokhov, “Proteolytically-cleaved fragments of cell-surface proteins from live tumor cells stimulate anti-tumor immune response in vitro,” Journal of Carcinogenesis & Mutagenesis, vol. 1, article 103, 2010. View at Publisher · View at Google Scholar
  17. E. E. Balashova and P. G. Lokhov, “Proteolytically-cleaved fragments of cell surface proteins stimulate a cytotoxic immune response against tumoractivated endothelial cells in vitro,” Journal of Cancer Science & Therapy, vol. 2, no. 5, pp. 126–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. E. E. Balashova, M. I. Dashtiev, and P. G. Lokhov, “Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence,” Molecular & Cellular Proteomics, vol. 11, no. 2, 2012. View at Publisher · View at Google Scholar · View at Scopus